Evidence map›Paper›PMID 23917377›Full record

ArticleCancer biology & therapy2013

ZC88, a novel 4-amino piperidine analog, inhibits the growth of neuroblastoma cells through blocking hERG potassium channel.

Xiaoli Wei, Hongliang Sun, Haitao Yan, Cheng Zhang, Shuzhuo Zhang, Xiaoyan Liu, Nan Hua, Xiaoyun Ma, Jianquan Zheng

Open access · bronzeAbstract read
In one paragraph

Article in Cancer biology & therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Xiaoli WeiBeijing Institute of Pharmacology and Toxicology, Beijing, China.
Hongliang Sun
Haitao Yan
Cheng Zhang
Shuzhuo Zhang
Xiaoyan Liu
Nan Hua
Xiaoyun Ma
Jianquan Zheng
Institute of Pharmacology · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many studies have provided convincing evidence for hERG as an important diagnostic and prognostic factor in human cancers, as well as a useful target for antineoplastic therapy. Our previous study also revealed that knockdown of herg gene expression by shRNA interference inhibited the growth of neuroblastoma cells in vitro and in vivo. In the experiment, a novel 4-amino piperidine analog, ZC88, was examined for its effect on hERG potassium channels and its antitumor potency was observed in vitro and in vivo. The results showed that ZC88 could block hERG1 and hERG1b channels expressed in Xenopus oocytes in a concentration-dependent manner. ZC88 displayed significant antiproliferative activity in several tumor cell lines and the tumor cells with higher expression of hERG presented higher sensitivity to ZC88. The mitotic progression of tumor cells was markedly suppressed in the presence of ZC88 through arresting cells in G₀/G₁ phase. ZC88 significantly inhibited the tumor growth in nude mice at a dosage with slight influence on the cardiac QT interval. The antitumor effect of ZC88 was correlated at least partly with its blockage of hERG channels, which implicated a positive role of hERG potassium channel in tumor cell proliferation.

Indexed as

AnimalsCell Line, TumorCell ProliferationDisease Models, AnimalEther-A-Go-Go Potassium ChannelsFemaleGuinea PigsHumansMaleMiceMice, NudeNeuroblastomaPiperidinesPotassium Channel BlockersTransfectionXenograft Model Antitumor AssaysEther-A-Go-Go Potassium ChannelsN-(1-(2,3-dimethoxyphenyl)-4-methyl-3-penten-1-yl)-1-(5-bromofurfuryl)-1-piperidyl-4-aminePiperidinesPotassium Channel Blockers4-aminopiperidinecancercell cyclehERGneuroblastomapotassium channelSH-SY5Y

Identifiers

PMID23917377
PMCPMC3672189
OpenAlexW2044142919

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.